Experts are rapidly investigating retatrutide, a innovative drug from Eli Lilly, as a potential step in weight loss . Unlike many earlier approaches, retatrutide is a twin-action receptor targeting simultaneously GLP-1 and GIP, chemicals that impact appetite and blood sugar control . Early clinical